Targeted Oncology reviews trending news online for the week of October 2, 2020, including updates in oncology and the latest conference coverage.
October marks both Breast Cancer Awareness Month and Liver Cancer Awareness Month. In recognition of these, Targeted Oncology spoke with 2 experts on the advancements that have been observed in recent years. Ghasson K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discussed the evolution of treatment options in hepatocellular carcinoma, while Daniel A. Vorobiof, MD, of Belong.Life, discussed the growing role of genomic testing in patients with breast cancer and how this impacts treatment decisions.
Check out the latest conference coverage from the 17th Annual International Society of Gastrointestinal Oncology Meeting.
FDA Grants Fast Track Designation to Eganelisib Combination in TNBC
A Fast Track designation was granted by the FDA to eganelisib (IPI-549) in combination with an immune checkpoint inhibitor and chemotherapy for the first-line treatment of patients with inoperable locally advanced or metastatic triple-negative breast cancer.
IV Sintilimab and Bevacizumab Biosimilar Improve Survival in Frontline Advanced HCC
The sintilimab injection (Tyvyt) in combination with IBI305 (Byvasda), a biosimilar to bevacizumab (Avastin), improved overall survival as well as progression-free survival compared with sorafenib (Nexavar) as frontline treatment of patients with advanced hepatocellular carcinoma, meeting the predefined primary end point of the phase 3 ORIENT-32 clinical trial.
Phase 3 HERO Study Update Demonstrates Promise for Relugolix in Advanced Prostate Cancer
Relugolix demonstrated a similar rate of castration resistance-free survival compared with the current standard of care leuprolide acetate as treatment of patients with metastatic prostate cancer.
New Drug Application Planned for Submission to FDA for Pacritinib in Myelofibrosis
A New Drug Application for pacritinib is planned to be submitted for potential accelerated approval from the FDA for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as platelet count less than 50 x 109/L.
2020 ESMO Recap: Oncology Community Unites to Bring Innovation to Patients With Cancer
Several experts in lung cancer, breast cancer, genitourinary cancers, and gastrointestinal cancers spoke with Targeted Oncology on some of the most impactful abstracts from the 2020 ESMO Congress.
Genomic Testing Is Necessary in Non-Small Cell Lung Cancer
Vivek Subbiah, MD, shares his take home message regarding the treatment of patients with non–small cell lung cancer who harbor a RET fusion.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
In season 1, episode 3 of Targeted Talks, a podcast, 2 experts in breast cancer discussed the treatment landscape and how precision medicine differs in the community versus academic settings.
PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer
March 27th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
TTFields Increases Time to Progression in Patients With Brain Metastases From NSCLC
March 27th 2024Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.
Read More